A pilot, multicentre, single-blind, randomized, placebo-controlled, parallel-group clinical trial, to assess the safety of Bilastine treatment regarding psychomotor performance using a virtual reality tool (AULA), in 9 to 11 years old children with allergic rhinitis and/or urticaria
Latest Information Update: 25 Sep 2019
At a glance
- Drugs Bilastine (Primary) ; Hydroxyzine
- Indications Allergic rhinoconjunctivitis; Urticaria
- Focus Adverse reactions
- Acronyms BiViClasS Project
- Sponsors FAES Farma
Most Recent Events
- 24 Sep 2019 Status changed from recruiting to completed.
- 30 Jan 2019 New trial record